FOXJ2

Across TCGA pan-cancer cohorts, FOXJ2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FOXJ2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FOXJ2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXJ2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

OV, CCRCC, and PDAC are the cancer types where FOXJ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Quartile	All	0.628	0.964	.036	16	view →
CCRCC	DFS	Median	All	0.897	0.648	.011	13	view →
PDAC	DFS	Quartile	III,IV	0.364	0.977	.010	9	view →
LUAD	OS	Quartile	All	0.974	1.000	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FOXJ2–OV (DFS)

Open the OV breakdown →